Peter Jüni

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Vahanian A, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Haugaa K, Jeppsson A, Jüni P, Pierard L, Prendergast B, Sádaba J, Tribouilloy C, Wojakowski W, Beyersdorf F

February 4, 2022 | 10.4244/EIJ-E-21-00009

Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis

Piccolo R, Oliva A, Avvedimento M, Franzone A, Windecker S, Valgimigli M, Esposito G, Jüni P

September 20, 2021 | 10.4244/EIJ-D-20-01197

Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes

Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys P, Hamm C, Steg G, Heg D, Branca M, Jüni P, Windecker S, Valgimigli M

October 23, 2020 | 10.4244/EIJ-D-20-00145

Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial

Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang C, Kogame N, Spitzer E, Buszman P, van Geuns R, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabaté M, Zmudka K, Rademaker-Havinga T, Tijssen J, Jüni P, Hamm C, Steg G, Onuma Y, Vranckx P, Valgimigli M, Windecker S, Baber U, Anderson R, Dominici M, Serruys P

April 3, 2020 | 10.4244/EIJ-D-19-00699

Will the Evolut Low Risk trial change my practice?

O'Sullivan C, Reardon M, Søndergaard L, Treede H, Jüni P, Windecker S

December 20, 2019 | 10.4244/EIJ-D-19-00587

Will the PARTNER 3 Low Risk Trial change my practice?

McConkey H, Modine T, Latib A, Jüni P, Windecker S, Leon MB

December 20, 2019 | 10.4244/EIJ-D-19-00847

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Serruys P, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen J, Rademaker-Havinga T, Garg S, Steg G, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F

December 20, 2019 | 10.4244/EIJ-D-19-00202

Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial

Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang C, Tomaniak M, Asano T, Katagiri Y, van Geuns R, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber CK, Sabaté M, Iqbal J, Wykrzykowska JJ, Piek J, Spitzer E, Jüni P, Hamm C, Steg G, Valgimigli M, Vranckx P, Windecker S, Serruys P

August 9, 2019 | 10.4244/EIJ-D-19-00184

Evaluating the importance of sham-controlled trials in the investigation of medical devices in interventional cardiology

Byrne RA, Capodanno D, Mahfoud F, Fajadet J, Windecker S, Jüni P, Baumbach A, Wijns W, Haude M

August 24, 2018 | 10.4244/EIJ-D-18-00481

A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial

Iglesias JF, Muller O, Zaugg S, Roffi M, Kurz D, Vuilliomenet A, Weilenmann D, Kaiser C, Tapponnier M, Heg D, Valgimigli M, Eeckhout E, Jüni P, Windecker S, Pilgrim T

August 24, 2018 | 10.4244/EIJ-D-17-00734

Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials

Cassese S, Byrne RA, Jüni P, Wykrzykowska JJ, Puricel S, Ndrepepa G, Schunkert H, Fusaro M, Cook S, Kimura T, Henriques J, Serruys P, Windecker S, Kastrati A

January 19, 2018 | 10.4244/EIJ-D-17-00492

Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary

Byrne RA, Stefanini G, Capodanno D, Onuma Y, Baumbach A, Escaned J, Haude M, James S, Joner M, Jüni P, Kastrati A, Oktay S, Wijns W, Serruys P, Windecker S

January 19, 2018 | 10.4244/EIJ20170912-01

The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction

Chin C, L’Allier P, Neumann F, Engstrøm T, Jüni P, Olivecrona G

August 4, 2017 | 10.4244/EIJV13I5A96

Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis

Noble S, Stortecky S, Heg D, Tueller D, Jeger RV, Toggweiler S, Ferrari E, Nietlispach F, Taramasso M, Maisano F, Grünenfelder J, Jüni P, Huber C, Carrel T, Windecker S, Wenaweser P, Roffi M

April 7, 2017 | 10.4244/EIJ-D-16-00677

Selective use of contemporary drug-eluting stents in primary angioplasty for ST-elevation myocardial infarction: pooled analysis of COMFORTABLE AMI and EXAMINATION

Baumbach A, Heg D, Räber L, Ostoijc M, Brugaletta S, Strange J, Johnson TW, Jüni P, Engstrøm T, Serruys P, Sabaté M, Windecker S

January 20, 2017 | 10.4244/EIJ-D-15-00408

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab A, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Jüni P, Windecker S

December 9, 2016 | 10.4244/EIJY15M12_09

Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial

Vranckx P, Valgimigli M, Windecker S, Steg G, Hamm C, Jüni P, Garcia-Garcia H, Van Es G-A, Serruys P

November 20, 2016 | 10.4244/EIJY15M11_07

External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation

Spitzer E, Hadorn S, Zanchin T, Yamaji K, Moschovitis A, Pilgrim T, Stortecky S, Jüni P, Heg D, Windecker S, Räber L

October 20, 2016 | 10.4244/EIJV12I9A185

Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial

Franzone A, Taniwaki M, Rigamonti F, Heg D, Piccolo R, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Jüni P, Windecker S, Pilgrim T

August 5, 2016 | 10.4244/EIJV12I5A99

Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials

Taniwaki M, Stefanini G, Räber L, Brugaletta S, Cequier A, Heg D, Iñiguez A, Kelbæk H, Serra A, Ostojic M, Hernández-Antolín R, Baumbach A, Blochlinger S, Jüni P, Mainar V, Sabaté M, Windecker S

August 20, 2015 | 10.4244/EIJY14M07_12

Peter Jüni

Latest news